Literature DB >> 26582646

Molecular prognostic factors in acute myeloid leukemia receiving first-line therapy with azacitidine.

J Desoutter1, J Gay2, C Berthon3, L Ades4, B Gruson5, S Geffroy1, I Plantier6, A Marceau1, N Helevaut1, J Fernandes7, M Bemba8, L Stalnikiewicz9, C Frimat1, J Labreuche10, O Nibourel1, C Roumier1, M Figeac11, P Fenaux12, B Quesnel3, A Renneville1, A Duhamel10, C Preudhomme1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26582646     DOI： 10.1038/leu.2015.314

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program.

Authors:  Luca Maurillo; Adriano Venditti; Alessandra Spagnoli; Gianluca Gaidano; Dario Ferrero; Esther Oliva; Monia Lunghi; Alfonso M D'Arco; Alessandro Levis; Domenico Pastore; Nicola Di Renzo; Alberto Santagostino; Vincenzo Pavone; Francesco Buccisano; Pellegrino Musto
Journal:  Cancer       Date:  2011-07-14       Impact factor: 6.860

2.  Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts.

Authors:  L H van der Helm; N J G M Veeger; M van Marwijk Kooy; A Beeker; O de Weerdt; M de Groot; C Alhan; M Hoogendoorn; L Laterveer; A A van de Loosdrecht; J Koedam; E Vellenga; G Huls
Journal:  Leuk Res       Date:  2013-04-28       Impact factor: 3.156

3.  Age and acute myeloid leukemia.

Authors:  Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf
Journal:  Blood       Date:  2006-02-02       Impact factor: 22.113

4.  International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

Authors:  Hervé Dombret; John F Seymour; Aleksandra Butrym; Agnieszka Wierzbowska; Dominik Selleslag; Jun Ho Jang; Rajat Kumar; James Cavenagh; Andre C Schuh; Anna Candoni; Christian Récher; Irwindeep Sandhu; Teresa Bernal del Castillo; Haifa Kathrin Al-Ali; Giovanni Martinelli; Jose Falantes; Richard Noppeney; Richard M Stone; Mark D Minden; Heidi McIntyre; Steve Songer; Lela M Lucy; C L Beach; Hartmut Döhner
Journal:  Blood       Date:  2015-05-18       Impact factor: 22.113

5.  High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

Authors:  Stefan Gröschel; Sanne Lugthart; Richard F Schlenk; Peter J M Valk; Karina Eiwen; Chantal Goudswaard; Wim J L van Putten; Sabine Kayser; Leo F Verdonck; Michael Lübbert; Gert-Jan Ossenkoppele; Ulrich Germing; Ingo Schmidt-Wolf; Brigitte Schlegelberger; Jürgen Krauter; Arnold Ganser; Hartmut Döhner; Bob Löwenberg; Konstanze Döhner; Ruud Delwel
Journal:  J Clin Oncol       Date:  2010-03-22       Impact factor: 44.544

6.  Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

Authors:  Pierre Fenaux; Ghulam J Mufti; Eva Hellstrom-Lindberg; Valeria Santini; Carlo Finelli; Aristoteles Giagounidis; Robert Schoch; Norbert Gattermann; Guillermo Sanz; Alan List; Steven D Gore; John F Seymour; John M Bennett; John Byrd; Jay Backstrom; Linda Zimmerman; David McKenzie; Cl Beach; Lewis R Silverman
Journal:  Lancet Oncol       Date:  2009-02-21       Impact factor: 41.316

7.  TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients.

Authors:  Rafael Bejar; Allegra Lord; Kristen Stevenson; Michal Bar-Natan; Albert Pérez-Ladaga; Jacques Zaneveld; Hui Wang; Bennett Caughey; Petar Stojanov; Gad Getz; Guillermo Garcia-Manero; Hagop Kantarjian; Rui Chen; Richard M Stone; Donna Neuberg; David P Steensma; Benjamin L Ebert
Journal:  Blood       Date:  2014-09-15       Impact factor: 22.113

8.  Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling.

Authors:  Erdogan Taskesen; Marije Havermans; Kirsten van Lom; Mathijs A Sanders; Yvette van Norden; Eric Bindels; Remco Hoogenboezem; Marcel J T Reinders; Maria E Figueroa; Peter J M Valk; Bob Löwenberg; Ari Melnick; Ruud Delwel
Journal:  Blood       Date:  2014-03-25       Impact factor: 22.113

9.  Prognostic value of TP53 gene mutations in myelodysplastic syndromes and acute myeloid leukemia treated with azacitidine.

Authors:  Cecile Bally; Lionel Adès; Aline Renneville; Marie Sebert; Virginie Eclache; Claude Preudhomme; Marie-Joelle Mozziconacci; Hugues de The; Jacqueline Lehmann-Che; Pierre Fenaux
Journal:  Leuk Res       Date:  2014-03-23       Impact factor: 3.156

10.  Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.

Authors:  Lisa Pleyer; Sonja Burgstaller; Michael Girschikofsky; Werner Linkesch; Reinhard Stauder; Michael Pfeilstocker; Martin Schreder; Christoph Tinchon; Thamer Sliwa; Alois Lang; Wolfgang R Sperr; Peter Krippl; Dietmar Geissler; Daniela Voskova; Konstantin Schlick; Josef Thaler; Sigrid Machherndl-Spandl; Georg Theiler; Otto Eckmüllner; Richard Greil
Journal:  Ann Hematol       Date:  2014-06-21       Impact factor: 3.673
View more
  5 in total

Review 1.  Treatment of Elderly Patients With Acute Myeloid Leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Curr Treat Options Oncol       Date:  2017-01

2.  NPM1 mutation is not associated with prolonged complete remission in acute myeloid leukemia patients treated with hypomethylating agents.

Authors:  Pedro Henrique Prata; Cécile Bally; Thomas Prebet; Christian Recher; Geoffroy Venton; Xavier Thomas; Emmanuel Raffoux; Arnaud Pigneux; Thomas Cluzeau; Judith Desoutter; Julie Gay; Claude Preudhomme; Pierre Fenaux; Lionel Adès
Journal:  Haematologica       Date:  2018-05-10       Impact factor: 9.941

Review 3.  How and when to decide between epigenetic therapy and chemotherapy in patients with AML.

Authors:  Hervé Dombret; Raphael Itzykson
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

4.  Superresolution imaging of individual replication forks reveals unexpected prodrug resistance mechanism.

Authors:  Therese Triemer; Alessandra Messikommer; Stella M K Glasauer; Jawad Alzeer; Miriam H Paulisch; Nathan W Luedtke
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-29       Impact factor: 11.205

5.  Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes.

Authors:  M Teresa Cedena; Inmaculada Rapado; Alejandro Santos-Lozano; Rosa Ayala; Esther Onecha; María Abaigar; Esperanza Such; Fernando Ramos; José Cervera; María Díez-Campelo; Guillermo Sanz; Jesús Hernández Rivas; Alejandro Lucía; Joaquin Martínez-López
Journal:  Oncotarget       Date:  2017-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.